{"entity":{"id":"transcenta","kind":"company","name":"Transcenta","aka":["Transcenta Holding","Suzhou Transcenta Therapeutics","创胜集团","HKEX:6628"],"tldr":"Transcenta is a Suzhou antibody company whose Claudin 18.2 antibody osemitamab (TST001) is being tested with nivolumab and chemotherapy as first-line treatment for stomach cancer.","summary":"Transcenta, listed in Hong Kong, develops antibodies with its own continuous-manufacturing platform. Osemitamab (TST001), a high-affinity Claudin 18.2 antibody with enhanced antibody-dependent cytotoxicity, has shown activity with nivolumab and chemotherapy in first-line gastric and gastro-oesophageal junction cancer and has orphan designations for gastric and pancreatic cancer. TST003 targets Gremlin1 in solid tumours and TST005 is a PD-L1 and TGF-beta bifunctional antibody.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.transcenta.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tst001","tst003"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.transcenta.com/","ticker":"HKEX:6628","stage":"public","investors":[],"funding":[]},"route":"/companies/transcenta/","neighbours":{"drug":[{"id":"tst001","kind":"drug","name":"TST001","route":"/drugs/tst001/"},{"id":"tst003","kind":"drug","name":"TST003","route":"/drugs/tst003/"}]}}